Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diels

Showing results (321-330 of 351) with videos related to

Pageof 36
Sort By:
The European Respiratory Journal|September 18, 2020
Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugsAgathe Jouet, Cyril Gaudin, Nelly Badalato, et al.
European Journal of Haematology|July 21, 2018
Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practiceEvangelos Terpos, Eirini Katodritou, Javier de la Rubia, et al.
Leukemia & Lymphoma|May 31, 2017
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimusGeorg Hess, Simon Rule, Wojciech Jurczak, et al.
Bioorganic & Medicinal Chemistry Letters|February 15, 2002
Synthesis and biological evaluation of imidazol-2-one and 2-cyanoiminoimidazole derivatives: novel series of PDE4 inhibitorsJ Ignacio Andrés, José M Alonso, Adolfo Díaz, et al.
Stem Cell Reports|July 31, 2018
Genetically Engineered iPSC-Derived FTDP-17 MAPT Neurons Display Mutation-Specific Neurodegenerative and Neurodevelopmental PhenotypesAn Verheyen, Annick Diels, Joke Reumers, et al.
Stem Cell Reports|August 15, 2019
Genetically Engineered iPSC-Derived FTDP-17 MAPT Neurons Display Mutation-Specific Neurodegenerative and Neurodevelopmental PhenotypesAn Verheyen, Annick Diels, Joke Reumers, et al.
Advances in Therapy|March 24, 2023
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple MyelomaPhilippe Moreau, Niels W C J van de Donk, Michel Delforge, et al.
Haematologica|December 22, 2022
Adjusted comparison of outcomes between patients from CARTITUDE-1 <i>versus</i> multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practiceMaria-Victoria Mateos, Katja Weisel, Thomas Martin, et al.
Lung Cancer (Amsterdam, Netherlands)|February 11, 2026
Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLCLuis Paz-Ares, Remi Veillon, Margarita Majem, et al.
JAMA Facial Plastic Surgery|May 10, 2019
An International Collaborative Standardizing Patient-Centered Outcome Measures in Pediatric Facial PalsyDaniel P Butler, Alethse De la Torre, Gregory H Borschel, et al.
Pageof 36

Showing results (321-330 of 351) with videos related to

Sort By:
Pageof 36
The European Respiratory Journal|September 18, 2020
Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugsAgathe Jouet, Cyril Gaudin, Nelly Badalato, et al.
European Journal of Haematology|July 21, 2018
Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practiceEvangelos Terpos, Eirini Katodritou, Javier de la Rubia, et al.
Leukemia & Lymphoma|May 31, 2017
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimusGeorg Hess, Simon Rule, Wojciech Jurczak, et al.
Bioorganic & Medicinal Chemistry Letters|February 15, 2002
Synthesis and biological evaluation of imidazol-2-one and 2-cyanoiminoimidazole derivatives: novel series of PDE4 inhibitorsJ Ignacio Andrés, José M Alonso, Adolfo Díaz, et al.
Stem Cell Reports|July 31, 2018
Genetically Engineered iPSC-Derived FTDP-17 MAPT Neurons Display Mutation-Specific Neurodegenerative and Neurodevelopmental PhenotypesAn Verheyen, Annick Diels, Joke Reumers, et al.
Stem Cell Reports|August 15, 2019
Genetically Engineered iPSC-Derived FTDP-17 MAPT Neurons Display Mutation-Specific Neurodegenerative and Neurodevelopmental PhenotypesAn Verheyen, Annick Diels, Joke Reumers, et al.
Advances in Therapy|March 24, 2023
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple MyelomaPhilippe Moreau, Niels W C J van de Donk, Michel Delforge, et al.
Haematologica|December 22, 2022
Adjusted comparison of outcomes between patients from CARTITUDE-1 <i>versus</i> multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practiceMaria-Victoria Mateos, Katja Weisel, Thomas Martin, et al.
Lung Cancer (Amsterdam, Netherlands)|February 11, 2026
Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLCLuis Paz-Ares, Remi Veillon, Margarita Majem, et al.
JAMA Facial Plastic Surgery|May 10, 2019
An International Collaborative Standardizing Patient-Centered Outcome Measures in Pediatric Facial PalsyDaniel P Butler, Alethse De la Torre, Gregory H Borschel, et al.
Pageof 36